PlainPharmaWatch

CMS Open Payments · Program Year 2024

Sumitomo Pharma America, Inc.

Sumitomo Pharma America, Inc. reported $48,075,723.50 in payments to 94,811 physicians and teaching hospitals across 106,116 transactions.

See the rankings → How this is sourced
$48.1M
Total payments
106,116
Transactions
94,811
Recipients
−$1.7M
General Payments vs PY2023

Sumitomo Pharma America, Inc. reported $48,075,723.50 in payments to 94,811 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #49 of 1,925 reporting manufacturers (0.3% of all US industry payments), averaging $507.07 per recipient across 6 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the editorial team.

The verdict

Sumitomo Pharma America, Inc. pairs top-5% payment volume with an unusually diversified payment pattern across a wide recipient base.

#49
of 1,925 companies
0.3%
of all US industry payments
0.0%
paid to its single top recipient
6
payment categories

Release-over-release change

General Payments changed from PY2023 to PY2024

Sumitomo Pharma America, Inc.'s CMS-reported General Payments decreased by $1.7M (−30.5%) from PY2023 to PY2024. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.

CMS source labels for this exact identifier: PY2023: SUMITOMO PHARMA AMERICA, INC.PY2024: Sumitomo Pharma America, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$5.5MPY2024$3.8M
PY2023
$5,478,809.67
PY2024
$3,805,644.96

How Sumitomo Pharma America, Inc. ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

Sumitomo Pharma America, Inc.'s total vs. every reporting company

CMS Open Payments, Program Year 2024

$48,075,724 Top 2% higher than 98% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). Below this entry. $25,112–$78,003: 249 reporting companies (13%). Below this entry. $78,003–$242,294: 295 reporting companies (15%). Below this entry. $242,294–$752,621: 270 reporting companies (14%). Below this entry. $752,621–$2,337,813: 263 reporting companies (14%). Below this entry. $2,337,813–$7,261,783: 200 reporting companies (10%). Below this entry. $7,261,783–$22,556,757: 133 reporting companies (7%). Below this entry. $22,556,757–$70,066,439: 45 reporting companies (2%). This entry sits in this band. $70,066,439–$217,642,369: 26 reporting companies (1%). Above this entry. $217,642,369–$676,046,922: 13 reporting companies (1%). Above this entry. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for Sumitomo Pharma America, Inc.

Averaging $453.05 per transaction and $507.07 per recipient, Sumitomo Pharma America, Inc.'s Program Year 2024 total comes to $48,075,723.50 across 106,116 transactions and 94,811 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #49 of 1,925 companies, representing 0.3% of all industry payments reported nationwide for the year.

"Food and Beverage" leads the 6-category general-payment breakdown below at $1.9M (3.9% of the company's reported total, 93,174 transactions) - see our methodology for how research and ownership payments are reported separately.

General Payment Breakdown by Type

Sumitomo Pharma America, Inc. made 6 types of general payments. "Food and Beverage" is the largest category at $1.9M, 3.9% of the company's reported total.

How Sumitomo Pharma America, Inc. divides its payments

Top payment categories by total reported dollar volume

1. Food and Beverage$1.9M2. Consulting Fee$892.8K3. Compensation for Services…$750.5K4. Grant$216.0K5. Travel and Lodging$75.3K6. Education$2.4K
Payment Type Amount Transactions
Food and Beverage $1.9M 93,174
Consulting Fee $892.8K 275
Compensation for Services Other Than Consulting $750.5K 1,031
Grant $216.0K 43
Travel and Lodging $75.3K 173
Education $2.4K 115

Recipient Concentration in General Payments

The five largest recipient relationships account for $417,497.85 (11.0%) of $3,805,644.96 in this company's General Payments records across 31,102 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Sumitomo Pharma America, Inc.

The five named recipients with the highest reported General Payments from this company

William White$119.9KThe Childrens Hospital of Ph…$99.4KMatt Rosenberg$75.1KDavid Staskin$65.6KAviva Asnis-Alibozek$57.5K
  1. 1

    William White

    $119,915.00 across 11 reported transactions

  2. 2

    The Childrens Hospital of Philadelp

    $99,360.00 across 11 reported transactions

  3. 3

    Matt Rosenberg

    $75,097.66 across 67 reported transactions

  4. 4

    David Staskin

    $65,628.72 across 43 reported transactions

  5. 5

    Aviva Asnis-Alibozek

    $57,496.47 across 11 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Payment Size Analysis

Average transaction size: $453.05. Average per recipient: $507.07.

Total Amount

$48,075,723.50

Avg per Transaction

$453.05

Avg per Recipient

$507.07

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

Sumitomo Pharma America, Inc. Share

0.3%

#49 by total payments

Companies with Similar Payment Volumes

Pharmaceutical companies with payment totals similar to Sumitomo Pharma America, Inc.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)

$47.9M 137,083 recipients

Cleerly, Inc.

$47.5M 910 recipients

Scientia Vascular

$46.9M 191 recipients

Novo Nordisk AS

$49.2M 804 recipients

Vektor Medical Inc.

$49.6M 56 recipients

Smith+Nephew, Inc.

$50.5M 71,450 recipients

Frequently Asked Questions

How much did Sumitomo Pharma America, Inc. pay to physicians and hospitals in 2024? ▾
In Program Year 2024, CMS Open Payments recorded $48,075,723.50 from Sumitomo Pharma America, Inc. to physicians and hospitals across 106,116 transactions - 0.3% of all industry payments reported that year.
How many physicians received payments from Sumitomo Pharma America, Inc.? ▾
94,811 physicians and teaching hospitals received payments from Sumitomo Pharma America, Inc. in 2024, averaging $507.07 per recipient.
What types of payments did Sumitomo Pharma America, Inc. make? ▾
General payments from Sumitomo Pharma America, Inc. span 6 distinct categories, covering things like consulting, meals, and travel. The largest general-payment category was "Food and Beverage" at $1.9M, representing 3.9% of the company's reported total.
How does Sumitomo Pharma America, Inc. rank among pharmaceutical companies? ▾
By total payment amount, Sumitomo Pharma America, Inc. sits at #49 of 1,925 companies in the CMS Open Payments database for 2024.
What is the average payment size from Sumitomo Pharma America, Inc.? ▾
The average transaction from Sumitomo Pharma America, Inc. was $453.05 in 2024. The company made 106,116 total transactions to 94,811 recipients.
Where does the payment data for Sumitomo Pharma America, Inc. come from? ▾
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Sumitomo Pharma America, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.